作为牛皮的二线疗法,布罗达卢马布:在生物学失败后的快速反应和独特的作用机制
Lawrence Green1, April Armstrong2, George Han3
1George Washington University School of Medicine, 2300 Eye Street Northwest, Washington, DC, USA. drgreen@looking-younger.com.
Dermatology and therapy
|September 19, 2025
概括
布罗达卢马布为在先前有生物学失败的成年人中适度至严重的斑块性牛皮提供了有效的二线治疗. 它通过阻断多个互白素17 (IL-17) 途径来证明快速和持久的疗效,解决治疗耐药性.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 治疗失败是管理中度至重度斑块性牛皮的一个重大挑战.
- 许多患者在初始的生物疗法中无法获得足够的反应.
- 对于先前有系统治疗失败的患者,需要替代治疗选择.
研究的目的:
- 评估布罗达卢马布作为二线治疗斑块性牛皮的临床证据.
- 评估布罗达卢马布在有生物学治疗失败史的患者中的疗效.
- 综合关于布罗达卢马布在治疗耐药牛皮的作用的证据.
主要方法:
- 临床试验,现实研究和观察性研究的叙述性综述.
- 在经过治疗的成年人群中分析布罗达卢马布的疗效.
- 检查布罗达卢马布针对IL-17受体A的作用机制.
主要成果:
- 布罗达卢马布表现出快速的牛皮区域和严重性指数反应率.
- 该药物在以前用其他生物药物治疗的患者中表现出持久的疗效.
- 它独特的阻断多个IL-17家族成员的机制有助于在耐药病例中的有效性.
结论:
- 布罗达卢马布是一种可行的,有效的二线治疗方案,用于斑块性牛皮.
- 证据支持布罗达卢马布在以前生物疗法失败的患者中的疗效.
- 临床医生可以考虑布罗达卢马布用于治疗耐药的牛皮.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
499
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
499
Inflammatory Bowel Disease IV: Pharmacological Management
528
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
528
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
439
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
439
Drug Products: Biologics, Biosimilars and Interchangeables
235
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
235
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
493
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
493
Drugs for Treatment of Ulcerative Colitis in IBD
463
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
463


